https://orcid.org/0000-0003-0229-2513
References
- Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, et al. A review of human carcinogens–part B: biological agents. Lancet Oncol. 2009;10:321‐322. doi:10.1016/S1470-2045(09)70096-8.
- de Sanjose S, WG Q, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al. Retrospective international survey and HPV time trends study group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–56. doi:10.1016/S1470-2045(10)70230-8.
- Guo F, Hirth JM, Berenson AB. Human Papillomavirus vaccination and pap smear uptake among young women in the United States: role of provider and patient. J Womens Health (Larchmt). 2017;26:1114–22. doi:10.1089/jwh.2017.6424.
- Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr., Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364:401–11. doi:10.1056/NEJMoa0909537.
- Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr., Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH. HPV vaccine against anal HPV infection and anal intraepitherial neoplasia. N Engl J Med. 2011;365:1576–85. doi:10.1056/NEJMoa1010971.
- [accessed 2020 May 25]. http://path.azureedge.net/media/documents/GrobalHPVVaccineIntroOverviewSlideswebversion2020May.pdf
- The Ministry of Health, Labour and Welfare. [accessed 2020 May 25]. http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou28/pdf/kankoku_h25_6_01.pdf.
- Nakagawa S, Ueda Y, Yagi A, Ikeda S, Hiramatsu K, Kimura T. Corrected human papillomavirus vaccination rates for each birth fiscal year in Japan. Cancer Sci. 2020. doi:10.1111/cas.14406.
- Community health/health promotion business report data by municipalities. [accessed 2020 May 25]. http://www.e-stat.go.jp/
- Taniguchi M, Ueda Y, Yagi A, Ikeda S, Endo M, Tomimatsu T, Nakayama T, Sekine M, Enomoto T, Kimura T. Cervical cancer screening rate differs by HPV vaccination status: an interim analysis. Vaccine. 2019;37:4424–26. doi:10.1016/j.vaccine.2019.06.064.
- Yagi A, Ueda Y, Egawa-Takata T, Tanaka Y, Morimoto A, Terai Y, Ohmichi M, Ichimura T, Sumi T, Murata H, et al. Development of an efficient strategy to improve HPV immunization coverage in Japan. BMC Public Health. 2016;16:1013. doi:10.1186/s12889-016-3676-7.
- Egawa-Takata T, Ueda Y, Morimoto A, Tanaka Y, Yagi A, Terai Y, Ohmichi M, Ichimura T, Sumi T, Murata H, et al. Motivating mothers to recommend their 20-year-old daughters receive cervical cancer screening: a randomized study. J Epidemiol. 2018;28:156–60. doi:10.2188/jea.JE20160155.